There are eight firms with a “buy” rating and three analysts with a “sell” rating. There is a one-year price target of $16.75, according to the report.
JPMorgan Chase & Co., reiterated the “neutral” rating with a price target at $14.67 earlier this week. Last week, Beaufort Securities reiterated the “sell” rating.
This past Monday, Smith & Nephew’s Julie Brown sold 4,227 shares on the open market at $17 per share for a total transaction reaching $71,869.19.
More articles on surgery:
5 key notes on delayed spine surgery after traumatic central cord syndrome
Power vs. manual tools for scoliosis surgery—5 key notes
5 things to know about adult spinal deformity surgical revision rates
